香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 今海醫療科技股份有限公司 （股份代號：2225） （於開曼群島註冊成立的成員有限責任公司） 董事會會議日期 Jinhai Medical Technology Limited 今海醫療科技股份有限公司 董事會主席兼執行董事 陳國寶 香港，二零二五年八月十五日 於本公告日期，董事會由八名董事組成，其中三名執行董事為陳國寶先生、王振飛 先生及李雲平先生；兩名非執行董事為蔣江雨先生及王華生先生；及三名獨立非 執行董事為嚴健軍先生、范一民先生及楊美華女士。 今海醫療科技股份有限公司（「本公司」）董事會（「董事會」）謹此宣佈，將於二零 二五年八月二十九日舉行董事會會議，旨在考慮及批准（其中包括）刊發本公司及 其附屬公司截至二零二五年六月三十日止六個月之中期業績及派發中期股息（如 適用）。 承董事會命 ...

Market Overview - The Hong Kong stock market continued its downward trend, with all three major indices in the red but maintaining above the 25,000 mark. The Hang Seng Index closed down 0.98% at 25,270.07 points, with a total turnover of HKD 31.27 billion [1] - Short-term market focus is on mid-year performance and cost-effectiveness, with potential volatility from US-China trade negotiations and fluctuations in US stocks [1] Blue-Chip Stocks Performance - JD Health (06618) led blue-chip stocks, rising 11.67% to HKD 61.25, contributing 11.31 points to the Hang Seng Index. The company's H1 2025 performance exceeded market expectations due to strong growth in the pharmaceutical category [2][4] - Other notable blue-chip movements included Xinyi Solar (00968) up 5.96%, Alibaba Health (00241) up 4.92%, while New World Development (00016) and Henderson Land (00012) saw declines of 5.35% and 4.63% respectively [2] Sector Highlights - Internet healthcare stocks showed strong performance, with Dingdang Health (09886) up 36.07% and JD Health (06618) up 11.67% following strong mid-year results [3][4] - The brokerage sector saw significant gains, with CITIC Securities (06066) up 10.98% and Zhongtai Securities (01375) up 9.03%, reflecting a structural shift in fund flows towards financial markets [5][6] - The photovoltaic sector also experienced gains, driven by a shortage and price increases in solar components, with Xinyi Solar (00968) rising 8.15% [6][7] Regulatory Developments - The Hong Kong Monetary Authority and the Securities and Futures Commission issued a joint statement regarding recent market fluctuations related to stablecoins, emphasizing a cautious approach to licensing [8] Notable Stock Movements - Silver诺医药-B (02591) surged 206.48% on its debut, reflecting strong market interest in GLP-1 drug treatments [9] - Liken Technology (00558) rose 46.02% following a strategic partnership for magnesium alloy humanoid robot development [10] - Far East China (02789) saw an 84.34% increase after announcing a profit forecast for H1 2025, driven by international market orders [11][12] - Jin Hai Medical Technology (02225) fell 50.56% after announcing a share subscription at a discount to market price [13]

今海医疗科技(02225)发布公告，认购事项的所有先决条件已获达成，并于2025年8月15日完成。合共1.2 亿股认购股份已按每股股份1.35港元的认购价成功发行予认购人的代名人。认购股份占紧接完成前本公 司现有已发行股本的2.32%;及经配发及发行认购股份扩大后的本公司已发行股本的约2.27%。 认购事项的所得款项总额约为1.62亿港元。认购事项的所得款项净额(经扣除相关成本及开支后)合共约 为1.61亿港元。本集团拟将认购事项的所得款项用于为潜在併购医疗保健相关项目及/或公司及投资医 疗保健相关产业提供资金;研发开支;及一般营运资金。 ...

Core Viewpoint - As of August 15, 2023, Jin Hai Medical Technology (02225.HK) experienced a significant decline in stock price, closing at HKD 0.890, down 50.56% from the previous trading day, with an intraday low of HKD 0.550, marking a new low for the past year [1] Group 1: Company Overview - Jin Hai Medical Technology Co., Ltd. (stock code: 2225) primarily operates as a service provider, with its subsidiary KT&T Group of Companies located in Singapore, offering labor dispatch and supporting services to local construction contractors [1] - The company has expanded its services beyond pure construction labor and resource provision to become a comprehensive solution provider for space management, including dormitory services, IT services, warehousing, cleaning, and building maintenance [1] Group 2: Business Strategy - The company aims to leverage the advantages of both Hong Kong and Singapore as platforms for external operations, actively seeking to expand existing businesses while entering new industries and exploring investment cooperation opportunities to enhance long-term returns for the company and its shareholders [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 今海醫療科技股份有限公司 呈交日期： 2025年8月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | | 是 | | | | 證券代號 (如上市) | 02225 | 說明 | | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要約。 Jinhai Medical Technology Limited 1 對本公司股權架構的影響 下文分別列出本公司(i)緊接完成前；及(ii)緊隨完成後之股權架構： | | 緊接完成前 | | 緊隨完成後 | | | --- | --- | --- | --- | --- | | | 股份數目 | 概約百分比 | 股份數目 | 概約百分比 | | 寶來國際有限公司 | | | | | | （附註1） | 2,530,000,000 | 48.94 | 2,530,000,000 | 47.82 | | 認購人A | – | – | 40,000,000 | 0.76 | | 認購人B | – | – | 40,000,000 | 0.76 | | 認購人C | – | – | 40,000,000 | 0.76 | | 其他公眾股 ...

Key Points - As of August 15, a total of 133 stocks reached their 52-week highs, with notable performers including 瑞港建设 (RuiGang Construction) at 94.74%, 力劲科技 (LiJing Technology) at 60.74%, and 派格生物医药－Ｂ (PAG Biopharma-B) at 39.18% [1] - The highest closing prices were recorded for 瑞港建设 at 0.260, 力劲科技 at 6.790, and 派格生物医药－Ｂ at 32.000 [1] - Other significant stocks that reached new highs include FIT HON TENG at 5.970 (26.04%), 远大中国 at 0.153 (25.81%), and 百心安－Ｂ at 6.060 (25.60%) [1] - The report also highlights stocks that reached their 52-week lows, with 今海医疗科技 (JinHai Medical Technology) dropping to 0.890 (-49.45%) and 恒泰裕集团 (HengTai Yu Group) at 0.014 (-12.50%) [4] - The overall market trend indicates a mix of strong performers and struggling stocks, reflecting varying investor sentiments across different sectors [1][4]

公告称，集团拟将认购事项所得款项用于为潜在并购医疗保健相关项目及╱或公司及投资医疗保健相关 产业提供资金；研发开支；及一般营运资金。 本文源自智通财经网 智通财经获悉，今海医疗科技(02225)盘中跌超36%，早盘一度跌超65%。截至发稿，跌36.11%，报1.15 港元，成交额1.61亿港元。 消息面上，今海医疗科技近期发布公告，公司(作为发行人)就认购事项与三名认购人订立三份认购协 议，以认购价每股股份1.35港元认购合共1.2亿股认购股份。各认购人为独立私人投资者。认购价为每股 股份1.35港元，较于认购协议日期联交所所报收市价每股股份1.64港元折让约17.68%；认购事项所得款 项净额(经扣除认购事项所有适用成本及开支)将约为1.6亿港元，而净发行价约为每股认购股份1.34港 元。 ...

Core Viewpoint - Jin Hai Medical Technology (02225) experienced a significant decline in stock price, dropping over 36% during trading, with an intraday drop exceeding 65% [1] Group 1: Stock Performance - As of the report, the stock price fell by 36.11%, trading at HKD 1.15, with a trading volume of HKD 161 million [1] - The stock's decline is attributed to the announcement of a subscription agreement with three independent private investors [1] Group 2: Subscription Agreement Details - The company entered into three subscription agreements to issue a total of 120 million shares at a subscription price of HKD 1.35 per share [1] - The subscription price represents a discount of approximately 17.68% compared to the closing price of HKD 1.64 on the date of the agreement [1] - The net proceeds from the subscription, after deducting applicable costs and expenses, are expected to be around HKD 160 million, with a net issuance price of approximately HKD 1.34 per share [1] Group 3: Use of Proceeds - The company plans to use the proceeds from the subscription for potential acquisitions in the healthcare sector, funding for healthcare-related projects, research and development expenses, and general working capital [1]

Core Viewpoint - Jin Hai Medical Technology (02225) experienced a significant decline in stock price, dropping over 36% during trading, with an intraday drop exceeding 65% [1] Group 1: Stock Performance - As of the report, the stock price of Jin Hai Medical Technology was down 36.11%, trading at 1.15 HKD, with a trading volume of 161 million HKD [1] - The company announced a subscription agreement with three independent private investors to issue a total of 120 million shares at a subscription price of 1.35 HKD per share [1] Group 2: Subscription Details - The subscription price of 1.35 HKD represents a discount of approximately 17.68% compared to the closing price of 1.64 HKD on the date of the subscription agreement [1] - The net proceeds from the subscription, after deducting all applicable costs and expenses, are expected to be around 160 million HKD, with a net issuance price of approximately 1.34 HKD per share [1] Group 3: Use of Proceeds - The company plans to use the proceeds from the subscription for potential acquisitions in the healthcare sector, funding for healthcare-related projects, research and development expenses, and general working capital [1]